Get the Stockscreener App
173.97
2.27%
-4.04
Praxis Precision Medicines Inc stock is traded at $173.97, with a volume of 526.68K.
It is down -2.27% in the last 24 hours and up +255.26% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$178.01
Open:
$180.93
24h Volume:
526.68K
Relative Volume:
0.68
Market Cap:
$3.66B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-18.97
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-8.43%
1M Performance:
+255.26%
6M Performance:
+383.25%
1Y Performance:
+146.73%
1-Day Range:
$168.16
$181.00
1-Week Range:
$164.75
$192.96
52-Week Range:
$26.70
$205.89
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
173.97 | 4.43B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
How Praxis Precision Medicines Inc. stock valuations compare to rivalsQuarterly Portfolio Summary & Community Consensus Trade Signals - newser.com
Is Praxis Precision Medicines Inc. stock near bottom after declineEarnings Summary Report & AI Forecast Swing Trade Picks - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.Volume Spike & Daily Momentum Trading Reports - newser.com
How to use Fibonacci retracement on Praxis Precision Medicines Inc.Weekly Stock Recap & Long-Term Growth Plans - newser.com
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beatJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com
Applying big data sentiment scoring on Praxis Precision Medicines Inc.Weekly Earnings Recap & Low Volatility Stock Suggestions - newser.com
What valuation multiples suggest for Praxis Precision Medicines Inc. stock - newser.com
Is Praxis Precision Medicines Inc a good long term investmentInsider Trading Activity & Affordable Investment Portfolio - earlytimes.in
Finance Watch: Where There’s A Will, Biopharma Finds A Way - Citeline News & Insights
Published on: 2025-10-24 12:07:23 - newser.com
Does Praxis Precision Medicines Inc. qualify in momentum factor screening2025 Market Outlook & Low Drawdown Momentum Trade Ideas - newser.com
Published on: 2025-10-23 02:39:16 - newser.com
Is Praxis Precision Medicines Worth a Closer Look After 261.8% Surge on Trial Results? - Yahoo Finance
Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor - Insider Monkey
Price momentum metrics for Praxis Precision Medicines Inc. explainedJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com
Rapid Rise of PRAX: Essential Tremor Breakthrough - StocksToTrade
Multi asset correlation models including Praxis Precision Medicines Inc. - newser.com
Praxis Precision Medicines, Inc. Announces FDA Type B Meeting for Ulixacaltamide - TradingView
12 Reddit Stocks That Will Go to the Moon - Insider Monkey
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Published on: 2025-10-20 08:35:46 - newser.com
Wedbush lifts Praxis Precision Medicines PT; shares down - TradingView
Largest borrow rate increases among liquid names - TipRanks
Published on: 2025-10-20 07:35:45 - newser.com
Wedbush Boosts Price Target on Praxis Precision Medicines to $73 From $33, Keeps Underperform Rating - MarketScreener
Praxis Precision Medicines Announces Underwritten Offering - TradingView
Praxis surges after late-stage trial success for movement disorder therapy - MSN
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):